Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1984 3
1986 1
1987 1
1988 1
1989 2
1990 1
1991 3
1992 7
1993 11
1994 10
1995 18
1996 26
1997 15
1998 10
1999 25
2000 30
2001 30
2002 22
2003 25
2004 34
2005 26
2006 38
2007 20
2008 39
2009 41
2010 50
2011 45
2012 61
2013 79
2014 108
2015 156
2016 242
2017 338
2018 380
2019 487
2020 563
2021 591
2022 506
2023 470
2024 493
2025 637
2026 205

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,274 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for sequencing circulating tumor dna
Your search for seqeuncing circulating tumor dna retrieved no results
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Kurtz DM, et al. Nat Biotechnol. 2021 Dec;39(12):1537-1547. doi: 10.1038/s41587-021-00981-w. Epub 2021 Jul 22. Nat Biotechnol. 2021. PMID: 34294911 Free PMC article.
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current detection methods reduces its utility for diagnosing minimal residual disease. Here we describe phased variant enrichment and detection …
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current …
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.
Deveson IW, Gong B, Lai K, LoCoco JS, Richmond TA, Schageman J, Zhang Z, Novoradovskaya N, Willey JC, Jones W, Kusko R, Chen G, Madala BS, Blackburn J, Stevanovski I, Bhandari A, Close D, Conroy J, Hubank M, Marella N, Mieczkowski PA, Qiu F, Sebra R, Stetson D, Sun L, Szankasi P, Tan H, Tang LY, Arib H, Best H, Burgher B, Bushel PR, Casey F, Cawley S, Chang CJ, Choi J, Dinis J, Duncan D, Eterovic AK, Feng L, Ghosal A, Giorda K, Glenn S, Happe S, Haseley N, Horvath K, Hung LY, Jarosz M, Kushwaha G, Li D, Li QZ, Li Z, Liu LC, Liu Z, Ma C, Mason CE, Megherbi DB, Morrison T, Pabón-Peña C, Pirooznia M, Proszek PZ, Raymond A, Rindler P, Ringler R, Scherer A, Shaknovich R, Shi T, Smith M, Song P, Strahl M, Thodima VJ, Tom N, Verma S, Wang J, Wu L, Xiao W, Xu C, Yang M, Zhang G, Zhang S, Zhang Y, Shi L, Tong W, Johann DJ Jr, Mercer TR, Xu J; SEQC2 Oncopanel Sequencing Working Group. Deveson IW, et al. Nat Biotechnol. 2021 Sep;39(9):1115-1128. doi: 10.1038/s41587-021-00857-z. Epub 2021 Apr 12. Nat Biotechnol. 2021. PMID: 33846644 Free PMC article.
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. ...We evaluated each stage of the ctDNA sequencing workflow with sim …
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensi …
Serial Circulating Tumor DNA Analysis with a Tumor-Naive Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.
Heo J, Kim YN, Shin S, Lee K, Lee JH, Lee YJ, Choi Z, Park J, Min S, Kim SW, Choi JR, Kim S, Lee ST, Lee JY. Heo J, et al. Cancer Res. 2024 Feb 1;84(3):468-478. doi: 10.1158/0008-5472.CAN-23-1429. Cancer Res. 2024. PMID: 38038965
Circulating tumor DNA (ctDNA) may aid in personalizing ovarian cancer therapeutic options. ...SIGNIFICANCE: In ovarian cancer, serial circulating tumor DNA testing is a highly predictive marker of patient survival, with a significantly im …
Circulating tumor DNA (ctDNA) may aid in personalizing ovarian cancer therapeutic options. ...SIGNIFICANCE: In ovarian …
Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing.
Herreros-Villanueva M, Bujanda L, Ruiz-Rebollo L, Torremocha R, Ramos R, Martín R, Artigas MC. Herreros-Villanueva M, et al. Gastroenterol Hepatol. 2022 Oct;45(8):637-644. doi: 10.1016/j.gastrohep.2021.12.011. Epub 2022 Jan 31. Gastroenterol Hepatol. 2022. PMID: 35092761 Review. English, Spanish.
BACKGROUND: Pancreatic cancer remains one of the most devastating malignancies due to the absence of techniques for early diagnosis and the lack of target therapeutic options for advanced disease. Next Generation Sequencing (NGS) generates high throughput and valuable gene …
BACKGROUND: Pancreatic cancer remains one of the most devastating malignancies due to the absence of techniques for early diagnosis and the …
Circulating tumor DNA in lymphoma: technologies and applications.
Fu L, Zhou X, Zhang X, Li X, Zhang F, Gu H, Wang X. Fu L, et al. J Hematol Oncol. 2025 Mar 11;18(1):29. doi: 10.1186/s13045-025-01673-7. J Hematol Oncol. 2025. PMID: 40069858 Free PMC article. Review.
Lymphoma, a malignant tumor derived from lymphocytes and lymphoid tissues, presents with complex and heterogeneous clinical manifestations, requiring accurate patient classification for appropriate treatment. ...Computed tomography (CT) and positron emission tomography/com …
Lymphoma, a malignant tumor derived from lymphocytes and lymphoid tissues, presents with complex and heterogeneous clinical manifesta …
Analytical evaluation of circulating tumor DNA sequencing assays.
Li W, Huang X, Patel R, Schleifman E, Fu S, Shames DS, Zhang J. Li W, et al. Sci Rep. 2024 Feb 29;14(1):4973. doi: 10.1038/s41598-024-54361-w. Sci Rep. 2024. PMID: 38424110 Free PMC article.
In China, circulating tumor DNA analysis is widely used and numerous assays are available. Systematic evaluation to help users make informed selections is needed. Nine circulating tumor DNA assays, including one benchmark assay, we …
In China, circulating tumor DNA analysis is widely used and numerous assays are available. Systematic evaluation …
Technical progress in circulating tumor DNA analysis using next generation sequencing.
Bai Y, Wang Z, Liu Z, Liang G, Gu W, Ge Q. Bai Y, et al. Mol Cell Probes. 2020 Feb;49:101480. doi: 10.1016/j.mcp.2019.101480. Epub 2019 Nov 8. Mol Cell Probes. 2020. PMID: 31711827 Review.
Circulating tumor DNA (ctDNA) is tumor-derived, fragmented DNA that circulates freely in body fluids, predominantly in the peripheral blood. Recently, ctDNA analysis has been suggested as a complement to tissue biopsy in the detection and …
Circulating tumor DNA (ctDNA) is tumor-derived, fragmented DNA that circulates freely in body fluids, pre …
Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling.
Chen LT, Jager M, Rebergen D, Brink GJ, van den Ende T, Vanderlinden W, Kolbeck P, Pagès-Gallego M, van der Pol Y, Besselink N, Moldovan N, Hami N, Kloosterman WP, van Laarhoven H, Mouliere F, Zweemer R, Lipfert J, Derks S, Marcozzi A, de Ridder J. Chen LT, et al. Genome Res. 2025 Apr 14;35(4):886-899. doi: 10.1101/gr.279144.124. Genome Res. 2025. PMID: 39805703 Free PMC article.
Shallow genome-wide cell-free DNA sequencing holds great promise for noninvasive cancer monitoring by providing reliable copy number alteration (CNA) and fragmentomic profiles. Single-nucleotide variations (SNVs) are, however, much harder to identify with low seq …
Shallow genome-wide cell-free DNA sequencing holds great promise for noninvasive cancer monitoring by providing reliable copy …
Direct detection of early-stage cancers using circulating tumor DNA.
Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE. Phallen J, et al. Sci Transl Med. 2017 Aug 16;9(403):eaan2415. doi: 10.1126/scitranslmed.aan2415. Sci Transl Med. 2017. PMID: 28814544 Free PMC article.
We have developed an approach called targeted error correction sequencing (TEC-Seq) that allows ultrasensitive direct evaluation of sequence changes in circulating cell-free DNA using massively parallel sequencing. ...In patients with resectable …
We have developed an approach called targeted error correction sequencing (TEC-Seq) that allows ultrasensitive direct evaluation of …
Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.
Mauri D, Kamposioras K, Matthaios D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, Papadimitriou K, Petricevic B, Kountourakis P, Kopecky J, Grašič Kuhar C, Popovic L, Chilingirova NP, De Mello RA, Dedić Plavetić N, Katsanos K, Mostert B, Alongi F, de Bari B, Corradini S, Kampletsas E, Gazouli I, Gkoura S, Amylidi AL, Valachis A. Mauri D, et al. Oncol Res Treat. 2022;45(4):216-221. doi: 10.1159/000521845. Epub 2022 Jan 9. Oncol Res Treat. 2022. PMID: 34999585 Free article. Review.
SUMMARY: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of soph …
SUMMARY: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extra …
5,274 results